Mobius (Memantine Hydrochloride)

Memantine works as a non‑competitive antagonist of the NMDA receptor. By blocking the receptor‑associated ion channel, it limits excessive calcium influx caused by over‑activation of glutamate, thereby protecting neurons from excitotoxic injury while preserving normal neurotransmission.

The dose of Mobius is determined by the prescribing clinician based on the patient’s condition, renal function, and tolerability. No fixed regimen is provided here; the prescriber will set the appropriate dosage and titration schedule.

Safety of memantine during pregnancy and lactation has not been established. The potential benefits must be weighed against possible risks, and use is generally reserved for situations where no suitable alternative exists and the prescriber deems it necessary.

To order Mobius, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas the most common alternative for Alzheimer’s disease is the acetylcholinesterase‑inhibitor class (e.g., donepezil). Memantine targets glutamate‑mediated excitotoxicity, while acetylcholinesterase inhibitors enhance cholinergic transmission. Clinical practice often uses them together for complementary effects.

Mobius should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency.

Mobius is taken orally, usually as a tablet. It can be swallowed with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include seizures, cardiac arrhythmias, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, hepatic injury, and emergence of suicidal thoughts or behavior. Patients should seek immediate medical attention if any of these events occur.

Mobius is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑receptor antagonists.